EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

기사 요약

IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.